Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland
Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland
复制标题
DOI：
10.1097/00000478-200304000-00009
复制
发表时间：
2003-04-01
影响因子：
5.6
通讯作者：
Lloyd, RV
中科院分区：
文献类型：
--
作者：
Gaffney, RL;Carney, JA;Lloyd, RV
Galectin-3 是一种 β-半乳糖苷结合凝集素，在许多肿瘤中过度表达，在区分良性和恶性甲状腺肿瘤时可能有用。最近，人们的兴趣集中在玻璃样变小梁肿瘤（HTT）的分类和生物学行为上。在这项研究中，我们比较了多种不同甲状腺肿瘤中的半乳糖凝集素 3 表达，以深入了解 HTT 的生物学行为。使用半乳糖凝集素 3 单克隆抗体对 153 例甲状腺肿瘤的福尔马林固定、石蜡包埋的组织进行染色。这些肿瘤包括 58 例 HTT、60 例乳头状癌、21 例滤泡性癌和 14 例滤泡性腺瘤。三位观察者将反应性分为阴性、弱或强。 HTT、乳头状癌和滤泡性腺瘤患者的平均患者年龄相似。滤泡癌患者的年龄比所有其他组的患者大约大十岁。所有类别的甲状腺肿瘤在女性患者中发生的频率更高。随访显示乳头状癌 (36.6%) 和滤泡状癌 (19%) 患者存在转移性疾病，但滤泡性腺瘤或 HTT 患者未发现转移性疾病。 Galectin-3 免疫染色显示 60% 的 HTT 呈阴性或具有弱 (H) (1+) 染色，40% 具有强 (2-3+) 染色。在大多数反应性病例中，染色是弥漫性的并且主要是细胞质的。 60 例乳头状癌中的 50 例 (83%) 和 21 例滤泡性癌中的 11 例 (52%) 显示出强烈的免疫染色。免疫染色在大多数乳头状癌和滤泡状癌中也呈弥漫性。大多数癌症中观察到的强免疫反应性与大多数滤泡性腺瘤（93%）中相对较弱或阴性的免疫染色形成鲜明对比。 HTT 的免疫表型以半乳糖凝集素 3 表达为特征，介于良性和恶性甲状腺肿瘤之间，表明一些染色强的肿瘤可能表现得像癌，尽管我们的病例中没有注意到这一点。我们的研究表明，galectin-3 表达的可变模式可能反映了 HTT 和甲状腺乳头状癌之间生物学行为的差异。
Galectin-3, a beta-galactoside-binding lectin, is overexpressed in many neoplasms and may be useful when differentiating between benign and malignant thyroid neoplasms. Recently, interest has focused on the classification and biologic behavior of hyalinizing trabecular tumors (HTTs). In this study we compared galectin-3 expression in a number of different thyroid neoplasms to gain insight into the biologic behavior of HTT. Formalin-fixed, paraffin-embedded tissues from 153 thyroid neoplasms were stained with a monoclonal antibody to galectin-3. These tumors included 58 HTTs, 60 papillary carcinomas, 21 follicular carcinomas, and 14 follicular adenomas. Reactivity was graded as negative, weak, or strong by three observers. The average patient age was similar in the patients with HTTs, papillary carcinomas, and follicular adenomas. The patients with follicular carcinomas were approximately a decade older than all other groups of patients. All groups of thyroid neoplasms occurred more frequently in female patients. Follow-up revealed metastatic disease in patients with papillary (36.6%) and follicular carcinomas (19%) but not in patients with follicular adenomas or HTTs. Galectin-3 immunostaining showed that 60% of the HTTs were negative or had weak (H) (1+) staining and 40% had strong (2-3+) staining. In the majority of the reactive cases, staining was diffuse and predominantly cytoplasmic. Fifty of the 60 (83%) papillary carcinomas and I I of the 21 (52%) follicular carcinomas showed strong immunostaining. The immunostaining was also diffuse in the majority of papillary and follicular carcinomas. The strong immunoreactivity seen in most of the carcinomas was in contrast to the relatively weak or negative immunostaining in the majority of follicular adenomas (93%). The immunophenotype of HTT, as characterized by galectin-3 expression, is intermediate between that of benign and malignant thyroid tumors, suggesting that some tumors with strong staining may behave like carcinomas, although this was not noted in our cases. Our study suggests that the variable pattern of galectin-3 expression may reflect a difference in biologic behavior between HTT and papillary thyroid carcinoma.